keyword
MENU ▼
Read by QxMD icon Read
search

antiemetics for chemotherapy

keyword
https://www.readbyqxmd.com/read/29655943/effects-of-a-histamine-h-4-receptor-antagonist-on-cisplatin-induced-anorexia-in-mice
#1
Kouichi Yamamoto, Rikuya Okui, Atsushi Yamatodani
Cancer chemotherapy often induces gastrointestinal symptoms such as anorexia, nausea, and vomiting. Antiemetic agents are effective in inhibiting nausea and vomiting, but patients still experience anorexia. We previously reported that chemotherapeutic agent-induced anorexia is associated with an increase of inflammatory cytokines. Other studies also reported that antagonism of the histamine H4 receptor is anti-inflammatory. In this study, we investigated the involvement of the H4 receptor in the development of chemotherapy-induced anorexia in mice...
April 12, 2018: Neuroscience Letters
https://www.readbyqxmd.com/read/29651918/updated-report-on-incidence-of-infusion-site-reactions-associated-with-peripheral-intravenous-administration-of-fosaprepitant
#2
Eric Chau, Jordan Lundberg, Gary Phillips, Michael Berger, Robert Wesolowski
Purpose Fosaprepitant (Emend®) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented an overall 28.7% incidence of infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These data resulted in a practice change within our institution; fosaprepitant is administered in more dilute concentrations over 30 min to prevent these adverse events. This retrospective study explored the impact of this practice change on the incidence of infusion-site reactions...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29564625/a-randomized-open-label-non-inferiority-study-to-compare-palonosetron-and-ondansetron-for-prevention-of-acute-chemotherapy-induced-vomiting-in-children-with-cancer-receiving-moderate-or-high-emetogenic-chemotherapy
#3
Sandeep Jain, Gauri Kapoor, Sahitya Koneru, Gayatri Vishwakarma
BACKGROUND: Chemotherapy-induced vomiting is a common adverse effect of cancer treatment. We assessed the non-inferiority of palonosetron versus ondansetron in prevention of acute chemotherapy-induced vomiting in children with cancer in 2-18 years of age. METHODS: In this single-center, open-label, randomized study, children receiving moderate and high emetogenic chemotherapy were assigned to get either ondansetron or palonosetron in addition to other antiemetic prophylaxis...
March 22, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29556813/bringing-it-all-together-in-the-treatment-of-cinv-application-of-current-knowledge-into-routine-clinical-practice
#4
David Warr
For patients with cancer, the threat of chemotherapy-induced nausea and vomiting (CINV) can greatly influence treatment decisions and overall quality of life. Clinicians now have numerous effective antiemetic therapies to offer to patients, but selecting the optimal strategy can be complicated. Integration of current CINV guidelines, emerging data from recent clinical trials, and patient-specific risk factors can greatly improve antiemetic prophylaxis. Two challenging clinical scenarios are presented and discussed to provide insight on how to best approach these types of treatment decisions and apply recent advances in CINV prevention and management to patient care...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29556812/getting-it-right-the-first-time-recent-progress-in-optimizing-antiemetic-usage
#5
Lee Schwartzberg
Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29556809/guidelines-versus-individualized-care-for-the-management-of-cinv
#6
Mark Clemons
Numerous groups have published guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). The current management of CINV, however, remains suboptimal, due in part to poor adherence to existing antiemetic guidelines. Challenges in clinical trial design have also slowed progress and complicated the selection of optimal antiemetic therapy. In addition, patient-specific characteristics and factors are not included in current CINV guidelines and are an important contributor to an individual's risk for nausea and vomiting...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29556808/cinv-still-troubling-patients-after-all-these-years
#7
Matti Aapro
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. The emergence of receptor antagonists targeting serotonin and neurokinin-1 have revolutionized the prevention of CINV, significantly reducing the impact of this side effect and improving patient quality of life...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29548068/managing-nausea-and-vomiting-in-patients-with-cancer-what-works
#8
Rudolph M Navari
The approach to the treatment of nausea and vomiting in a cancer patient should begin with a complete assessment, including the frequency, duration, and intensity of the nausea/vomiting; associated activities; and whether anorexia or cachexia is present. It is important to determine whether the nausea and vomiting is related to treatment (chemotherapy, radiation) or is independent of cancer treatment. Nausea/vomiting unrelated to chemotherapy and/or radiation may have an etiology for which there is a specific and potentially successful intervention...
March 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29547608/cisplatin-based-therapy-and-cinv-optimal-antiemetics-during-germ-cell-testicular-cancer-treatment
#9
Meghan Mastrangelo
BACKGROUND: Cisplatin-based chemotherapy regimens are the backbone of chemotherapy for germ cell testicular cancer. Cisplatin is administered for five days, causing an overlap of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Although CINV is widely researched, studies involving multiday chemotherapy regimens are limited. OBJECTIVES: This article synthesizes the research in antiemetics used in multiday cisplatin-based chemotherapy regimens and provides recommendations to optimize antiemetic therapy...
April 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29509270/medical-use-of-cannabis-italian-and-european-legislation
#10
S Zaami, A Di Luca, N M Di Luca, G Montanari Vergallo
This review illustrates some brief considerations of the medical use of cannabis recently issued in Italy. History and uses of cannabis throughout centuries and different countries are illustrated together with a description of botany and active phytocannabinoids. Then, medical use of cannabis anti-pain treatment for patients resistant to conventional therapies is described in case of chronic neuropathic pain, spasticity, for anticinetosic and antiemetic effect in nausea and vomiting caused by chemotherapy, for appetite stimulating effect in cachexia, anorexia, loss of appetite in cancer patients or patients with AIDS and in anorexia nervosa, hypotensive effect in glaucoma resistant to conventional therapies and for reduction of involuntary body and facial movements in Gilles de la Tourette syndrome...
February 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29503734/oral-rehydration-solution-os-1-as-a-substitute-of-intravenous-hydration-after-cisplatin-administration-in-patients-with-lung-cancer-a-prospective-multicenter-trial
#11
Hidehito Horinouchi, Kaoru Kubota, Akihiko Miyanaga, Shinji Nakamichi, Masahiro Seike, Akihiko Gemma, Yuki Yamane, Futoshi Kurimoto, Hiroshi Sakai, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Tomohide Tamura, Yuichiro Ohe
Background: The aim of this trial was to evaluate the safety and efficacy of oral hydration as a substitute for intravenous hydration after cisplatin (CDDP) administration. Methods: The major eligibility criteria included patients with lung cancer, indications for a CDDP-based regimen at a dose of 60 mg/m2 or higher, an age of between 20 and 74 years and adequate renal function. Antiemetic prophylaxis consisted of an appropriate dose of palonosetron, aprepitant, dexamethasone and magnesium sulfate (8 mEq)...
2018: ESMO Open
https://www.readbyqxmd.com/read/29503435/-role-of-pharmacists-in-completion-of-adjuvant-cisplatin-vinorelbine-chemotherapy-in-japanese-patients-with-non-small-cell-lung-cancer
#12
Yoshihito Morimoto, Hidefumi Takei, Keisei Tachibana, Yoko Nakazato, Ryota Tanaka, Yasushi Nagashima, Kazuhiro Watanabe, Reisuke Seki, Takao Shinohara, Haruhiko Kondo
 Adjuvant cisplatin-vinorelbine chemotherapy has been shown to be effective in patients with completely resected non-small cell lung cancer (NSCLC) in several Phase III trials, but not yet in the Japanese population. Pharmacists are expected to assist patients with completion of adjuvant chemotherapy. The aim of this retrospective study was to evaluate the compliance with and safety of adjuvant cisplatin-vinorelbine chemotherapy in Japanese patients and to evaluate the contribution of pharmacists to completion of treatment...
2018: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/29459665/a-randomized-placebo-controlled-pilot-trial-of-aprepitant-combined-with-standard-antiemetic-therapy-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-undergoing-cyclophosphamide-based-conditioning-regimens-prior-to-hematopoietic-stem
#13
Joseph Bubalo, Kelsey Mulverhill, Gabrielle Meyers, Brandon Hayes-Lattin, Richard Maziarz
The aim of this study was to evaluate the safety and efficacy of aprepitant when used prophylactically to prevent nausea and vomiting during cyclophosphamide-based conditioning regimens. The primary objective of this study was to determine if there was a difference in the number of emesis-free days in patients who received aprepitant as compared to those who received placebo. This prospective, randomized, double blind, placebo-controlled study was performed in 40 adult patients who received a cyclophosphamide-containing HSCT conditioning regimen...
February 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29421926/hydration-requirements-with-emetogenic-chemotherapy-granisetron-extended-release-subcutaneous-versus-palonosetron
#14
Jeffrey Vacirca, Dennis Caruana, George Calcanes, Michael Mosier, Ralph Boccia, Ali McBride
AIM: This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention. MATERIALS & METHODS: At a community practice, CINV-related hydration per chemotherapy cycle was determined following highly (HEC) or moderately emetogenic chemotherapy (MEC) and a guideline-recommended antiemetic regimen: neurokinin 1 receptor antagonist, dexamethasone and either palonosetron only, GERSC only, or palonosetron switched to GERSC...
February 9, 2018: Future Oncology
https://www.readbyqxmd.com/read/29417850/efficacy-of-ginger-in-ameliorating-acute-and-delayed-chemotherapy-induced-nausea-and-vomiting-among-patients-with-lung-cancer-receiving-cisplatin-based-regimens-a-randomized-controlled-trial
#15
Xiangfeng Li, Ying Qin, Wei Liu, Xiao-Yu Zhou, Ya-Nan Li, Li-Ying Wang
Nausea and vomiting are among the most common and distressing side effects of chemotherapy. Additional antiemetic drugs are urgently needed to effectively manage and ameliorate chemotherapy-induced nausea and vomiting (CINV). The efficacy of ginger as an antiemetic modality for ameliorating CINV has not been established in previous studies. The aim of this study was to examine the efficacy of ginger, as an adjuvant drug to standard antiemetic therapy, in ameliorating acute and delayed CINV in patients with lung cancer receiving cisplatin-based regimens...
February 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29416232/the-role-of-neurokinin-1-substance-p-antagonists-in-the-prevention-of-postoperative-nausea-and-vomiting
#16
Dionne Okafor, Alan David Kaye, Rachel J Kaye, Richard D Urman
Postoperative nausea and vomiting (PONV) can be very debilitating for surgical patients, and effective management reduces potential morbidity, aiding in patient satisfaction, and minimizing the need for unintended hospital stays. Risk factors include female sex, nonsmoker, and having a previous history of motion sickness or PONV. Anesthetic risk factors include receiving opioids, not receiving a total intravenous anesthetic (TIVA), exposure to nitrous oxide, and extended length of anesthetic. Many treatments, including serotonin antagonists, dopamine antagonists, corticosteroids, inhaled isopropyl alcohol, and anticholinergics, as well as techniques such as TIVA, have been utilized over recent decades in an attempt to reduce PONV incidence...
October 2017: Journal of Anaesthesiology, Clinical Pharmacology
https://www.readbyqxmd.com/read/29385389/compatibility-and-stability-of-varubi-rolapitant-injectable-emulsion-admixed-with-intravenous-granisetron-hydrochloride
#17
George Wu, Dan Powers, Stanley Yeung, Frank Chen, Kelly Neelon
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine- 3 (5-HT3) RA, and dexamethasone is recommended by international antiemesis guidelines for the prevention of chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy and for select patients receiving moderately emetogenic chemotherapy. VARUBI (rolapitant) is a substance P/NK-1 RA that was recently approved by the U.S. Food and Drug Administration as an injectable emulsion in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy...
January 2018: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/29385388/compatibility-and-stability-of-varubi-rolapitant-injectable-emulsion-admixed-with-intravenous-palonosetron-hydrochloride-injection-and-dexamethasone-sodium-phosphate-injection
#18
George Wu, Dan Powers, Stanley Yeung, Frank Chen
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone is recommended by international antiemesis guidelines for the prevention of chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy and for selected patients receiving moderately emetogenic chemotherapy. VARUBI (rolapitant) is a substance P/NK-1 RA that was recently approved by the U.S. Food and Drug Administration as an injectable emulsion in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy...
January 2018: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/29374715/control-of-nausea-and-vomiting-in-patients-receiving-anthracycline-cyclophosphamide-chemotherapy-for-breast-cancer
#19
Minako Nawa-Nishigaki, Ryo Kobayashi, Akio Suzuki, Chiemi Hirose, Rie Matsuoka, Ryutaro Mori, Manabu Futamura, Tadashi Sugiyama, Kazuhiro Yoshida, Yoshinori Itoh
BACKGROUND/AIM: Chemotherapy-induced nausea and vomiting (CINV) is one of most distressing adverse events during cancer chemotherapy. In breast cancer patients receiving anthracycline and cyclophosphamide (AC) chemotherapy, CINV is poorly controlled. PATIENTS AND METHODS: The prevalence of guideline-consistent antiemetic medication and control of CINV were investigated retrospectively in breast cancer patients receiving the first cycle of AC chemotherapy. Risks for CINV were analyzed by the multivariate logistic regression analysis...
February 2018: Anticancer Research
https://www.readbyqxmd.com/read/29350695/prechemotherapy-education-reducing-patient-anxiety-through-nurse-led-teaching-sessions
#20
Emmanuel Apor, Nathan T Connell, Katherine Faricy-Anderson, Peter Barth, Rouba Youssef, Mary Fenton, William M Sikov, Anthony Thomas, Kayla Rosati, Andrew Schumacher, Alise Lombardo, Susan Korber, Humera Khurshid, Howard Safran, Anthony Mega
BACKGROUND: Patients with cancer experience stress surrounding diagnosis and treatment. Many cancer centers employ a nurse-led education session to alleviate patient anxiety and confusion.
. OBJECTIVES: The goal was to evaluate the effect of a nurse-led chemotherapy teaching session on patients' knowledge, anxiety, and preparedness for 
cancer-directed therapy.
. METHODS: After discussing treatment with their oncologist, participants completed a survey assessing their perceived understanding of various treatment topics...
February 1, 2018: Clinical Journal of Oncology Nursing
keyword
keyword
32975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"